// COMPANY
AnaCardio
SECTOR BIOTECHMENTIONS 2LAST SEEN OCTOBER 4, 2026
Discussed in
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
mention·The VC Corner·OCTOBER 4, 2026
“Biotech/medtech raises (TriGemX Bio, AnaCardio, ai3Bio, Aptadir Therapeutics)”
Source→02
funding·StrictlyVC·OCTOBER 2, 2026
“AnaCardio, a Stockholm drug developer for advanced heart failure that develops an oral drug designed to strengthen heart contractions, raised a $70.9M Series B.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.